MoonLake Immunotherapeutics (MLTX) Competitors $9.52 +0.06 (+0.63%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$9.56 +0.04 (+0.47%) As of 10/24/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLTX vs. DYN, BHC, SRPT, ETNB, MESO, OCUL, ANIP, VERA, COGT, and STOKShould you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Dyne Therapeutics (DYN), Bausch Health Cos (BHC), Sarepta Therapeutics (SRPT), 89BIO (ETNB), Mesoblast (MESO), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Cogent Biosciences (COGT), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. MoonLake Immunotherapeutics vs. Its Competitors Dyne Therapeutics Bausch Health Cos Sarepta Therapeutics 89BIO Mesoblast Ocular Therapeutix ANI Pharmaceuticals Vera Therapeutics Cogent Biosciences Stoke Therapeutics Dyne Therapeutics (NASDAQ:DYN) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Which has stronger earnings & valuation, DYN or MLTX? Dyne Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$317.42M-$3.86-4.44MoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.78-3.42 Which has more risk and volatility, DYN or MLTX? Dyne Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Do institutionals and insiders hold more shares of DYN or MLTX? 96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is DYN or MLTX more profitable? MoonLake Immunotherapeutics' return on equity of -40.98% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -64.12% -56.75% MoonLake Immunotherapeutics N/A -40.98%-35.81% Do analysts prefer DYN or MLTX? Dyne Therapeutics currently has a consensus target price of $34.07, suggesting a potential upside of 98.99%. MoonLake Immunotherapeutics has a consensus target price of $36.00, suggesting a potential upside of 278.15%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Dyne Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 4 Strong Buy rating(s) 2.94MoonLake Immunotherapeutics 2 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07 Does the media favor DYN or MLTX? In the previous week, MoonLake Immunotherapeutics had 28 more articles in the media than Dyne Therapeutics. MarketBeat recorded 32 mentions for MoonLake Immunotherapeutics and 4 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 0.63 beat MoonLake Immunotherapeutics' score of 0.12 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral SummaryMoonLake Immunotherapeutics beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks. Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLTX vs. The Competition Export to ExcelMetricMoonLake ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$611.48M$3.46B$6.21B$10.81BDividend YieldN/A2.28%5.72%4.81%P/E Ratio-3.4228.5131.5730.95Price / SalesN/A497.40595.06133.69Price / CashN/A46.9537.2561.86Price / Book1.3410.4012.056.61Net Income-$118.94M-$52.83M$3.34B$277.10M7 Day Performance4.39%2.10%1.93%2.57%1 Month Performance-83.11%12.33%7.77%3.79%1 Year Performance-79.61%14.14%56.40%33.01% MoonLake Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLTXMoonLake Immunotherapeutics2.8868 of 5 stars$9.52+0.6%$36.00+278.2%-79.4%$611.48MN/A-3.422Trending NewsAnalyst ForecastDYNDyne Therapeutics2.7171 of 5 stars$17.08+4.3%$34.07+99.5%-45.0%$2.33BN/A-4.42100Analyst ForecastBHCBausch Health Cos4.6692 of 5 stars$6.32+4.5%$9.00+42.4%-23.8%$2.24B$9.63B24.3220,700Positive NewsUpcoming EarningsAnalyst ForecastSRPTSarepta Therapeutics4.5342 of 5 stars$23.05+2.4%$34.42+49.3%-82.7%$2.20B$1.90B-26.491,372Positive NewsAnalyst ForecastGap UpETNB89BIO2.8614 of 5 stars$14.80+0.3%$25.81+74.4%+90.3%$2.19BN/A-4.1040News CoverageAnalyst ForecastShort Interest ↓MESOMesoblast1.9575 of 5 stars$17.65+3.4%$24.00+36.0%+93.9%$2.18B$17.20M0.0080Analyst ForecastOCULOcular Therapeutix4.3155 of 5 stars$12.18+2.9%$22.63+85.8%+5.5%$2.06B$63.72M-9.52230Positive NewsAnalyst ForecastANIPANI Pharmaceuticals3.8754 of 5 stars$95.12+0.3%$99.14+4.2%+59.0%$2.06B$614.38M-123.53600News CoveragePositive NewsAnalyst UpgradeVERAVera Therapeutics2.7011 of 5 stars$30.20-3.3%$61.50+103.6%-26.6%$1.99BN/A-8.4440News CoverageAnalyst ForecastCOGTCogent Biosciences2.3017 of 5 stars$16.22-1.0%$19.67+21.2%+26.0%$1.87BN/A-9.1180News CoverageAnalyst ForecastGap UpSTOKStoke Therapeutics3.2685 of 5 stars$34.65+3.3%$30.83-11.0%+167.9%$1.84B$36.56M40.77100Analyst Forecast Related Companies and Tools Related Companies DYN Competitors BHC Competitors SRPT Competitors ETNB Competitors MESO Competitors OCUL Competitors ANIP Competitors VERA Competitors COGT Competitors STOK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLTX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredUrgent Buy Alert: My Top Three Quantum Computing StocksQuantum computing is the hottest tech trend of the year... With some of these stocks jumping 700%, 2,800% a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MLTX Stock Alerts